Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis 

Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the monitoring, diagnosis, and management of cardiotoxicity in light chain (AL) amyloidosis. Close monitoring of cardiac biomarkers, such as NT-proBNP and high-sensitivity troponin, is essential. Adjusting treatment based on these biomarkers and patient functional status may be necessary. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.